Today: 3 July 2026
Intel stock (INTC) jumps nearly 7% as chip rally kicks off 2026 — what’s next
3 January 2026
1 min read

Intel stock (INTC) jumps nearly 7% as chip rally kicks off 2026 — what’s next

NEW YORK, Jan 3, 2026, 10:00 ET — Market closed

Intel Corp (INTC) shares closed up 6.7% at $39.38 on Friday, their latest move as U.S. markets sit closed for the weekend. The stock traded between $37.41 and $39.86 and logged about 95.4 million shares in volume.

The jump matters because semiconductors have been doing much of the heavy lifting for U.S. equities, and Intel remains a widely traded proxy for sentiment toward the group.

With January data and the fourth-quarter earnings season ahead, investors are testing whether the year-end pullback reset entry points for big tech and chip names, or simply delayed a broader rotation.

The rebound was broad across chipmakers. Nvidia gained 1.2%, Advanced Micro Devices rose 4.3% and U.S.-listed Taiwan Semiconductor Manufacturing climbed 5.2%, while the iShares Semiconductor ETF advanced 4.2%.

On Friday, the Dow and S&P 500 ended higher to start 2026, helped by chip stocks, while the Nasdaq finished roughly flat; the Philadelphia Semiconductor Index (.SOX) rose 4%, Reuters reported. “Buy the dip, sell the rip,” is the mentality in the market, Joe Mazzola, head of trading & derivatives strategist at Charles Schwab, told Reuters. Reuters

Policy risk stayed in focus over the weekend after President Donald Trump blocked a China-linked deal involving Emcore assets, citing national security concerns. The decision followed a review by the Committee on Foreign Investment in the United States (CFIUS), a U.S. panel that scrutinizes foreign investments for security risks.

For Intel, the move keeps attention on its push to regain momentum in PCs and data-center processors while scaling Intel Foundry — its contract manufacturing business, meaning it makes chips for itself and other companies. Outside-customer wins and execution on manufacturing are key swing factors for the stock.

Before the next session, traders are watching the U.S. employment report due Jan. 9 and the consumer price index (CPI) on Jan. 13 for rate signals, alongside a U.S. Supreme Court decision on Trump’s tariffs and the president’s choice of a new Federal Reserve chair, Reuters reported. Fed funds futures — a market-based gauge of expected rate moves — show little chance of a cut at the Fed’s late-January meeting and about a 50% chance of a quarter-point reduction in March.

Intel is estimated to report earnings on Jan. 29 after the close based on market calendars, though the company has not confirmed a date.

When Intel does report, investors will be watching demand trends and management’s outlook, along with any update on the cost of expanding manufacturing capacity and the trajectory of the foundry operation.

Technically, $40 is an immediate level in focus after Friday’s surge, with the next hurdle near Intel’s 52-week high of $44.02, according to Nasdaq data.

Any fresh signals on U.S. trade policy and export controls could also swing chip sentiment into the earnings rush, particularly as investors reassess valuations in AI-linked hardware names.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Raffles Medical Group (SGX:BSL) jumps after AI brain imaging partnership, valuation gap in focus
    July 3, 2026, 12:51 PM EDT. Raffles Medical Group (SGX:BSL) moved after a new partnership with Neurophet to provide AI software for brain MRI scans tied to neurodegenerative diseases. Shares traded at SGD0.93. The one-year shareholder return sits at -5.04%; year-to-date, the stock is down 8.82%. The P/E ratio is 24.3 times, which is below the peer group average of 29.4 but higher than the Asian healthcare industry's 19.9 and just above a calculated fair P/E of 23.8. A DCF model puts value 38.9% higher at SGD1.52, pointing to possible undervaluation. The market is weighing those potential gains against earnings risks and regulatory uncertainty in Singapore and Greater China.
Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus
Previous Story

Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom
Next Story

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Go toTop